GENOFOCUS, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4,220 KRW | +0.60% |
|
+1.93% | +8.07% |
| Sales 2022 | 27.8B 20.35M 1.7B | Sales 2023 | 27.01B 19.77M 1.65B | Capitalization | 88.87B 65.05M 5.42B |
|---|---|---|---|---|---|
| Net income 2022 | -12.97B -9.49M -791M | Net income 2023 | -2.95B -2.16M -180M | EV / Sales 2022 | 5.75 x |
| Net Debt 2022 | 37.09B 27.15M 2.26B | Net Debt 2023 | 32.48B 23.77M 1.98B | EV / Sales 2023 | 4.49 x |
| P/E ratio 2022 |
-9.46
x | P/E ratio 2023 |
-29.9
x | Employees | 66 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 66.29% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.60% | ||
| 1 week | +1.93% | ||
| Current month | +4.46% | ||
| 1 month | +4.46% | ||
| 3 months | +6.84% | ||
| 6 months | +40.43% | ||
| Current year | +8.07% |
1 week
3 975.00
4 250.00
1 month
3 590.005 270.00
Current year
3 590.005 270.00
1 year
2 800.006 150.00
3 years
2 800.0012 600.00
5 years
2 350.0019 350.00
10 years
2 350.0026 550.00
| Managers | Title | Age | Since |
|---|---|---|---|
Eui-Joong Kim
CEO | Chief Executive Officer | 51 | - |
Jae-Gu Pan
FOU | Founder | 66 | 29/00/29 |
Jong-Min Na
AUD | Comptroller/Controller/Auditor | 50 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jae-Gu Pan
FOU | Founder | 66 | 29/00/29 |
Eui-Joong Kim
CEO | Chief Executive Officer | 51 | - |
Jung-Hyeon Kim
BRD | Director/Board Member | 60 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 02/24/02 | 4,165 | -1.30% | 54,899 |
| 30/24/30 | 4,220 | +0.60% | 48,749 |
| 29/24/29 | 4,195 | +3.20% | 55,113 |
| 26/24/26 | 4,065 | +0.99% | 51,345 |
| 25/24/25 | 4,025 | -4.51% | 75,149 |
End-of-day quote Korea S.E., April 30, 2024
More quotes
GenoFocus, Inc. is a Korea-based company principally engaged in the development, manufacture and distribution of enzymes. The Company mainly manufactures catalases, lactase, phytases and other enzymes. The catalases are mainly used for industry, including processing of semiconductors, petroleum and propylene oxide, medical therapeutics, food processing, contact-lens and other industries. The lactases are mainly used for food processing including processing of milk, yogurt and milk serum. The phytases are mainly used for processing of animal feed. And the Company is exploring new businesses, engaged in development of other enzymes including therapeutic enzymes, chemical agents and others.
Sector
Commodity Chemicals
Calendar
13/05/2024
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +8.07% | 69.41M | |
| +2.80% | 103B | |
| +1.20% | 67.05B | |
| +44.29% | 40.4B | |
| +15.99% | 38.64B | |
| +4.15% | 32.41B | |
| +6.84% | 19.17B | |
| +12.32% | 16.76B | |
| +17.69% | 15.07B | |
| +8.31% | 14.82B |
- Stock Market
- Equities
- A187420 Stock
